Design Therapeutics, Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>Design Therapeutics, Inc. has filed its 2023 annual report (10-K) detailing its financial performance and operational aspects for the fiscal year ending December 31, 2023.</b>

AI Summary

Design Therapeutics, Inc. (DSGN) filed a Annual Report (10-K) with the SEC on March 19, 2024. Design Therapeutics, Inc. filed its 2023 Form 10-K on March 19, 2024. The filing covers the fiscal year ending December 31, 2023. The company is incorporated in Delaware and operates in the Pharmaceutical Preparations industry (SIC 2834). Key financial data points such as Accounts Payable and Other Accrued Liabilities, Restricted Stock, and Fair Value Inputs are referenced. The report includes details on various agreements and plans, including consulting agreements, stock options, and equity incentive award plans.

Why It Matters

For investors and stakeholders tracking Design Therapeutics, Inc., this filing contains several important signals. This 10-K filing provides a comprehensive overview of Design Therapeutics' financial health, operational activities, and strategic direction for the past fiscal year, which is crucial for investors to assess the company's current standing and future prospects. The detailed information within the filing, including financial statements, risk factors, and executive compensation, allows stakeholders to make informed decisions regarding their investment in the company.

Risk Assessment

Risk Level: medium — Design Therapeutics, Inc. shows moderate risk based on this filing. The company operates in the pharmaceutical industry, which is subject to significant regulatory oversight, lengthy development cycles, and substantial R&D costs, posing inherent risks to financial performance and market success.

Analyst Insight

Investors should review the detailed risk factors and financial statements in the 10-K to understand the specific challenges and opportunities facing Design Therapeutics in the pharmaceutical sector.

Key Numbers

• 2023-12-31 — Fiscal Year End (Conformed period of report)
• 2024-03-19 — Filing Date (As of date)
• 96 — Public Document Count (Total documents in the filing)
• 2834 — SIC Code (Pharmaceutical Preparations)

Key Players & Entities

• Design Therapeutics, Inc. (company) — Filer name
• 2023 (date) — Fiscal year end
• 2024-03-19 (date) — Filing date
• 2834 (industry) — Standard Industrial Classification
• DE (state) — State of incorporation
• Carlsbad (location) — Business address city
• 001-40288 (filing_number) — SEC file number
• Marlinspike Group LLC (company) — Consulting agreement

FAQ

Risk Factors

• Regulatory Risks [high — regulatory]: The pharmaceutical industry is subject to extensive government regulation, which can impact product development, approval, manufacturing, and marketing.
• Research and Development Costs [high — financial]: Significant investment in research and development is required, with no guarantee of successful product commercialization.
• Competition [medium — market]: The company faces intense competition from other pharmaceutical and biotechnology companies.
• Reliance on Key Personnel [medium — operational]: The success of the company may depend on the continued service of key scientific and management personnel.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 10-K.
• 2024-03-19: Filing Date — Date the 10-K was officially submitted to the SEC.

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share DSGN The Nasdaq

Filing Documents

• dsgn-20231231.htm (10-K) — 2578KB
• dsgn-ex4_3.htm (EX-4.3) — 37KB
• dsgn-ex10_7.htm (EX-10.7) — 38KB
• dsgn-ex10_13.htm (EX-10.13) — 23KB
• dsgn-ex10_14.htm (EX-10.14) — 98KB
• dsgn-ex23_1.htm (EX-23.1) — 7KB
• dsgn-ex31_1.htm (EX-31.1) — 16KB
• dsgn-ex32_1.htm (EX-32.1) — 10KB
• dsgn-ex97_1.htm (EX-97.1) — 43KB
• img217302005_0.jpg (GRAPHIC) — 22KB
• img217302005_1.jpg (GRAPHIC) — 1563KB
• img217302005_2.jpg (GRAPHIC) — 24KB
• img217302005_3.jpg (GRAPHIC) — 50KB
• img217302005_4.jpg (GRAPHIC) — 739KB
• img217302005_5.jpg (GRAPHIC) — 1175KB
• img217302005_6.jpg (GRAPHIC) — 1071KB
• img217302005_7.jpg (GRAPHIC) — 1202KB
• img217302005_8.jpg (GRAPHIC) — 524KB
• img217302005_9.jpg (GRAPHIC) — 392KB
• img217302005_10.jpg (GRAPHIC) — 242KB
• img217302005_11.jpg (GRAPHIC) — 34KB
• img217302005_12.jpg (GRAPHIC) — 426KB
• img217302005_13.jpg (GRAPHIC) — 419KB
• img217302005_14.jpg (GRAPHIC) — 509KB
• img217302005_15.jpg (GRAPHIC) — 331KB
• img217302005_16.jpg (GRAPHIC) — 26KB
• img217302005_17.jpg (GRAPHIC) — 599KB
• img217302005_18.jpg (GRAPHIC) — 16KB
• img217302005_19.jpg (GRAPHIC) — 178KB
• 0000950170-24-033492.txt (&nbsp;) — 34119KB
• dsgn-20231231.xsd (EX-101.SCH) — 1189KB
• dsgn-20231231_htm.xml (XML) — 1772KB

Business

Business 6 Item 1A.

Risk Factors

Risk Factors 55 Item 1B. Unresolved Staff Comments 111 Item 1C. Cybersecurity 112 Item 2.

Properties

Properties 113 Item 3.

Legal Proceedings

Legal Proceedings 113 Item 4. Mine Safety Disclosures 113 PART II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 114 Item 6. [Reserved] 114 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 115 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 124 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 125 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 147 Item 9A.

Controls and Procedures

Controls and Procedures 147 Item 9B. Other Information 147 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 147 PART III Item 10. Directors, Executive Officers and Corporate Governance 148 Item 11.

Executive Compensation

Executive Compensation 148 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 148 Item 13. Certain Relationships and Related Transactions, and Director Independence 148 Item 14. Principal Accounting Fees and Services 148 PART IV Item 15. Exhibits, Financial Statement Schedules 149 Item 16. Form 10-K Summary 150 2 PART I Special Note Regarding Forward-Looking Statements This Annual Report on Form 10-K and the information incorporated herein by reference contain forward-looking statements that involve risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this Annual Report are forward-looking statements. In some cases, you can identify forward-looking statements by words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "seek," "should," "target," "will," "would," or the negative of these words or other comparable terminology. These forward-looking statements include, but are not limited to, statements about: our plans to research, develop and commercialize our product candidates; our expectations for resuming clinical development of our program in Friedrich ataxia and announcing data therefrom and the timing thereof; the side effect profile observed in nonclinical testing of DT-216P2 being indicative of the side effect profile that may be expected in clinical studies, and in general the ability of DT-216P2 to prevent injection site thrombophlebitis or other limiting side effects; the initiation, progress, success, cost and timing of our nonclinical studies, clinical trials and product development activities; the therapeutic potential of our product candidates, and the disease indications for which w

View Full Filing

View this 10-K filing on SEC EDGAR